These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 22405469)
41. Biomarkers for subtypes of pancreatic ductal adenocarcinoma. Venkatesan P Lancet Oncol; 2017 Dec; 18(12):e718. PubMed ID: 29129444 [No Abstract] [Full Text] [Related]
42. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979 [TBL] [Abstract][Full Text] [Related]
43. Radiological evaluation of response to neoadjuvant treatment in pancreatic cancer. Cassinotto C; Sa-Cunha A; Trillaud H Diagn Interv Imaging; 2016 Dec; 97(12):1225-1232. PubMed ID: 27692675 [TBL] [Abstract][Full Text] [Related]
44. Amsterdam International Consensus Meeting: tumor response scoring in the pathology assessment of resected pancreatic cancer after neoadjuvant therapy. Janssen BV; Tutucu F; van Roessel S; Adsay V; Basturk O; Campbell F; Doglioni C; Esposito I; Feakins R; Fukushima N; Gill AJ; Hruban RH; Kaplan J; Koerkamp BG; Hong SM; Krasinskas A; Luchini C; Offerhaus J; Sarasqueta AF; Shi C; Singhi A; Stoop TF; Soer EC; Thompson E; van Tienhoven G; Velthuysen MF; Wilmink JW; Besselink MG; Brosens LAA; Wang H; Verbeke CS; Verheij J; Mod Pathol; 2021 Jan; 34(1):4-12. PubMed ID: 33041332 [TBL] [Abstract][Full Text] [Related]
45. Exocrine-endocrine pancreatic cancer and alpha-fetoprotein. Brandi G; Nobili E; Capizzi E; Corti B; Di Cicilia R; Di Marco M; Biasco G Pancreas; 2008 Aug; 37(2):223-5. PubMed ID: 18665089 [No Abstract] [Full Text] [Related]
46. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596 [TBL] [Abstract][Full Text] [Related]
47. Advanced pancreatic ductal adenocarcinoma - Complexities of treatment and emerging therapeutic options. Diwakarla C; Hannan K; Hein N; Yip D World J Gastroenterol; 2017 Apr; 23(13):2276-2285. PubMed ID: 28428707 [TBL] [Abstract][Full Text] [Related]
48. Modified Appleby procedure for borderline resectable/locally advanced distal pancreatic adenocarcinoma: A major procedure for selected patients. Cesaretti M; Abdel-Rehim M; Barbier L; Dokmak S; Hammel P; Sauvanet A J Visc Surg; 2016 Jun; 153(3):173-81. PubMed ID: 26775202 [TBL] [Abstract][Full Text] [Related]
51. Molecular biology of adenocarcinoma of the pancreatic duct, current state and future therapeutic avenues. Abbas S Surg Oncol; 2013 Jun; 22(2):69-76. PubMed ID: 23415924 [TBL] [Abstract][Full Text] [Related]
52. [Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma]. Kawaida H; Fujii H Nihon Rinsho; 2015 Mar; 73 Suppl 3():181-5. PubMed ID: 25857011 [No Abstract] [Full Text] [Related]
53. The spectrum of histopathological changes encountered in pancreatectomy specimens after neoadjuvant chemoradiation, including subtle and less-well-recognised changes. Kalimuthu SN; Serra S; Dhani N; Chetty R J Clin Pathol; 2016 Jun; 69(6):463-71. PubMed ID: 26915370 [TBL] [Abstract][Full Text] [Related]
54. American gastroenterological association institute guideline on the diagnosis and management of asymptomatic neoplastic pancreatic cysts. Vege SS; Ziring B; Jain R; Moayyedi P; ; Gastroenterology; 2015 Apr; 148(4):819-22; quize12-3. PubMed ID: 25805375 [No Abstract] [Full Text] [Related]
55. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157 [TBL] [Abstract][Full Text] [Related]
56. A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy. Neofytou K; Giakoustidis A; Smyth EC; Cunningham D; Mudan S J Surg Oncol; 2015 May; 111(6):768-70. PubMed ID: 25556724 [TBL] [Abstract][Full Text] [Related]
57. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Knudsen ES; O'Reilly EM; Brody JR; Witkiewicz AK Gastroenterology; 2016 Jan; 150(1):48-63. PubMed ID: 26385075 [TBL] [Abstract][Full Text] [Related]
58. Alteration of strain ratio evaluated by transabdominal ultrasound elastography may predict the efficacy of preoperative chemoradiation performed for pancreatic ductal carcinoma: preliminary results. Kawada N; Tanaka S; Uehara H; Katayama K; Hosoki T; Takami M; Tomita Y Hepatogastroenterology; 2014; 61(130):480-3. PubMed ID: 24901166 [TBL] [Abstract][Full Text] [Related]
59. [An Enhanced Multimodality Treatment Strategy in Pancreatic Ductal Carcinoma Requiring Heminephrectomy for Radical Resection - A Case Report]. Kitagawa A; Iwagami Y; Eguchi H; Yamada D; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Kobayashi S; Mori M; Doki Y Gan To Kagaku Ryoho; 2017 Nov; 44(12):1367-1369. PubMed ID: 29394636 [TBL] [Abstract][Full Text] [Related]
60. Update on the management of pancreatic cancer: surgery is not enough. Ansari D; Gustafsson A; Andersson R World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]